FDA Eases Rules for Cancer Tests to Speed Patient Access
Published Date: 6/11/2025
Proposed Rule
Summary
The FDA is changing the rules for certain cancer test kits called in situ hybridization (ISH) systems, making them easier to get approved by moving them from a strict category (class III) to a less strict one (class II). This means companies can bring these tests to market faster, but they still have to meet safety and quality checks. This update helps patients get important cancer treatments sooner without extra costs or delays.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
ISH Cancer Tests Reclassified to Class II
The FDA proposes to reclassify in situ hybridization (ISH) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes NYQ, MVD, OWE, and PNK) from class III (premarket approval) to class II (special controls). These devices would become subject to premarket notification instead of premarket approval, which the agency says enables companies to bring the tests to market faster and may speed patient access to the corresponding oncology treatments.
New Special Controls and Premarket Rules
FDA is proposing a new device classification regulation that sets out the special controls manufacturers must meet to provide a reasonable assurance of safety and effectiveness for these ISH test systems. Manufacturers would need to meet those special controls while using the class II pathway and premarket notification process.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
Previous / Next Documents
Previous: 2025-10548 — Air Plan Approval; West Virginia; 2024 Amendments to West Virginia's Ambient Air Quality Standards
The EPA is giving a thumbs-up to West Virginia’s updated air quality rules for 2024. This means the state will use the latest national air standards and monitoring methods to keep the air cleaner and safer. People and businesses in West Virginia should get ready for these changes, which help protect health without adding extra costs right now.
Next: 2025-10477 — Lower 37 GHz Band and Use of Spectrum Bands Above 24 GHz for Mobile Radio Service
The FCC wants to tighten rules for using super high-frequency airwaves above 37 GHz to keep things running smoothly and avoid interference. They’re asking for ideas on improving how companies share this space and exploring smarter, faster ways to manage it. This affects mobile service providers and could shape how new tech rolls out, with some rule fixes coming soon.